1-50 of 5,068 results for subject:Diabetes
Librarians' tools
- Search time
- 0.327 seconds
- Solr query time
- 0.014 seconds
- Search query
- subject:Diabetes
- We searched for
- subject_t:Diabetes OR subject_ses:9636
Type
House
Session
More
Year
More
Department
More
Member
More
Primary member
More
Answering member
More
Legislative stage
Legislation
More
Subject
More
Publisher
To ask the Secretary of State for Health and Social Care, whether she has assessed the potential impact of funding preventative interventions for people with pre-diabetes and early Type 2 diabetes on the economy.
To ask the Secretary of State for Health and Social Care, whether she has assessed the potential impact of funding preventative interventions for people with pre-diabetes and early Type 2 diabetes on the economy.
The eligibility criteria for continuous glucose monitoring amongst type 2 diabetics are set in guidance published by the National Institute for Health and Care Excellence. This guidance is available at the following link:
https://www.nice.org.uk/guidance/NG28
No assessment has been made, as continuous glucose monitoring devices have not been validated for the use of diagnosis of type 2 diabetes.
The Healthier You NHS Diabetes Prevention Programme, is highly effective in cutting the risk of developing type 2 diabetes by 37% for people completing the programme compared to those who do not attend.
Outcomes for the Type 2 Diabetes Path to Remission Programme demonstrates that 32% of programme completers achieved remission with an average weight loss of almost 16 kilograms.
To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential impact of earlier diagnosis and preventative technologies, including continuous glucose monitoring, on reducing the economic impact of Type 2 diabetes.
To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential impact of earlier diagnosis and preventative technologies, including continuous glucose monitoring, on reducing the economic impact of Type 2 diabetes.
The eligibility criteria for continuous glucose monitoring amongst type 2 diabetics are set in guidance published by the National Institute for Health and Care Excellence. This guidance is available at the following link:
https://www.nice.org.uk/guidance/NG28
No assessment has been made, as continuous glucose monitoring devices have not been validated for the use of diagnosis of type 2 diabetes.
The Healthier You NHS Diabetes Prevention Programme, is highly effective in cutting the risk of developing type 2 diabetes by 37% for people completing the programme compared to those who do not attend.
Outcomes for the Type 2 Diabetes Path to Remission Programme demonstrates that 32% of programme completers achieved remission with an average weight loss of almost 16 kilograms.
To ask the Secretary of State for Health and Social Care, what plans the department has to improve public awareness of peripheral neuropathy and early signs of diabetes-related foot complications.
To ask the Secretary of State for Health and Social Care, what plans the department has to improve public awareness of peripheral neuropathy and early signs of diabetes-related foot complications.
To ask the Secretary of State for Health and Social Care, what steps the department is taking to reduce the incidence of diabetes-related lower-limb amputations, including by improving early detection of peripheral neuropathy and access to preventative foot-care services.
To ask the Secretary of State for Health and Social Care, what steps the department is taking to reduce the incidence of diabetes-related lower-limb amputations, including by improving early detection of peripheral neuropathy and access to preventative foot-care services.
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help ensure that all Integrated Care Boards have access to multidisciplinary specialist foot-care teams for people with diabetes.
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to help ensure that all Integrated Care Boards have access to multidisciplinary specialist foot-care teams for people with diabetes.
Motion that this House has considered the potential merits of reform of the vascular sector. Agreed to question.
Motion that this House has considered the potential merits of reform of the vascular sector. Agreed to question.
I beg to move,
That this House has considered the potential merits of reform of the vascular sector.
It is a real pleasure to serve under your chairship, Dr Huq. Last night, you were in the Adjournment debate, and today you are chairing a Westminster Hall debate. Your talents are incredible—well done...
I beg to move,
That this House has considered the potential merits of reform of the vascular sector.
It is a real pleasure to serve under your chairship, Dr Huq. Last night, you were in the Adjournment debate, and today you are chairing a Westminster Hall debate. Your talents are incredible—well done...
The statistics that the hon. Gentleman highlights should shock us all. If those were the statistics for dealing with any cancer, we would simply find them unacceptable. Does he agree that vascular disease, because it is not treated in the same way as cancer, in some cases ends up being...
The statistics that the hon. Gentleman highlights should shock us all. If those were the statistics for dealing with any cancer, we would simply find them unacceptable. Does he agree that vascular disease, because it is not treated in the same way as cancer, in some cases ends up being...
I thank the hon. Gentleman for that intervention. He has rightly said that, when it comes to vascular disease, while it is equal with cancer in its severity and in the numbers who lose their lives, it is not treated the same. Today’s debate perhaps gives us a chance to...
I thank the hon. Gentleman for that intervention. He has rightly said that, when it comes to vascular disease, while it is equal with cancer in its severity and in the numbers who lose their lives, it is not treated the same. Today’s debate perhaps gives us a chance to...
It is a pleasure to serve under your chairmanship today, Dr Huq. I thank the hon. Member for Strangford (Jim Shannon) for securing this debate.
The publication of the 2026 cardiovascular disease modern service framework is a welcome step towards realising our commitment to a more preventative, community-focused health service. It...
It is a pleasure to serve under your chairmanship today, Dr Huq. I thank the hon. Member for Strangford (Jim Shannon) for securing this debate.
The publication of the 2026 cardiovascular disease modern service framework is a welcome step towards realising our commitment to a more preventative, community-focused health service. It...
It is a pleasure to serve under your chairship, Dr Huq. I welcome the Minister, my hon. Friend the Member for Bury North (Mr Frith), to his place—he knows that I was in his place not too long ago, and I will be kind to him in my asks. I...
It is a pleasure to serve under your chairship, Dr Huq. I welcome the Minister, my hon. Friend the Member for Bury North (Mr Frith), to his place—he knows that I was in his place not too long ago, and I will be kind to him in my asks. I...
It is a pleasure to serve under your chairship, Dr Huq. I welcome the Minister and the shadow Minister, the hon. Member for Solihull West and Shirley (Dr Shastri-Hurst), to their places. Most of all, I thank the hon. Member for Strangford (Jim Shannon) for securing this important debate. He...
It is a pleasure to serve under your chairship, Dr Huq. I welcome the Minister and the shadow Minister, the hon. Member for Solihull West and Shirley (Dr Shastri-Hurst), to their places. Most of all, I thank the hon. Member for Strangford (Jim Shannon) for securing this important debate. He...
It is a pleasure to serve under your chairmanship this afternoon, Dr Huq. As the hon. Member for Glasgow South West (Dr Ahmed)—I call him my hon. Friend—pointed out, I have a particular interest in this subject. It is a number of years since I held a licence to practise,...
It is a pleasure to serve under your chairmanship this afternoon, Dr Huq. As the hon. Member for Glasgow South West (Dr Ahmed)—I call him my hon. Friend—pointed out, I have a particular interest in this subject. It is a number of years since I held a licence to practise,...
It is a genuine pleasure to serve under your chairship, Dr Huq, and to join you again in Parliament. We worked together before and it is an honour to be here today.
As is customary, I would like to thank the hon. Member for Strangford (Jim Shannon) for securing this important...
It is a genuine pleasure to serve under your chairship, Dr Huq, and to join you again in Parliament. We worked together before and it is an honour to be here today.
As is customary, I would like to thank the hon. Member for Strangford (Jim Shannon) for securing this important...
The Minister is making a powerful case that to govern is to make decisions. Does he agree that when it comes to the NHS, while we talk a lot about money, input and investment, today we are ultimately talking about reform, taking different decisions and showing leadership? Does he agree...
The Minister is making a powerful case that to govern is to make decisions. Does he agree that when it comes to the NHS, while we talk a lot about money, input and investment, today we are ultimately talking about reform, taking different decisions and showing leadership? Does he agree...
I concur fully with my hon. Friend’s point. I noted his earlier remark about the commissioning of outcomes, and I think that one of the developing themes adjoining my own thinking and my brief is the need to get better at commissioning outcomes, considering whole populations, communities and places, and...
I concur fully with my hon. Friend’s point. I noted his earlier remark about the commissioning of outcomes, and I think that one of the developing themes adjoining my own thinking and my brief is the need to get better at commissioning outcomes, considering whole populations, communities and places, and...
I thank the Minister very much for that response; it is incredibly helpful. There seems to be a postcode lottery, where those who need care get it in some places but not in others. Does the Minister feel that his policy will ensure deliverability across all postcodes, not just in...
I thank the Minister very much for that response; it is incredibly helpful. There seems to be a postcode lottery, where those who need care get it in some places but not in others. Does the Minister feel that his policy will ensure deliverability across all postcodes, not just in...
That is a very fair and right challenge. This is not about endorsing patchwork provision; it is about understanding that, whether because of the physiological, social, environmental or behavioural differences that exist, care is not evenly distributed. We should have standards that we expect nationally, but we should also commission...
That is a very fair and right challenge. This is not about endorsing patchwork provision; it is about understanding that, whether because of the physiological, social, environmental or behavioural differences that exist, care is not evenly distributed. We should have standards that we expect nationally, but we should also commission...
I agree with the Minister that services should be locally commissioned, particularly where there is a high prevalence of a certain type of disease or condition, because it allows for the shaping of those services to local circumstances. There is evidence, is there not, that local commissioning has not given...
I agree with the Minister that services should be locally commissioned, particularly where there is a high prevalence of a certain type of disease or condition, because it allows for the shaping of those services to local circumstances. There is evidence, is there not, that local commissioning has not given...
I hope that my further remarks will address that very point; I am happy to pick it up with the hon. Member in due course if they do not satisfy.
ICBs will use national modern service frameworks set by the Government and guidance to create the right services for their areas....
I hope that my further remarks will address that very point; I am happy to pick it up with the hon. Member in due course if they do not satisfy.
ICBs will use national modern service frameworks set by the Government and guidance to create the right services for their areas....
I thank the Minister for his generosity in giving us a chance to ask questions. One of the areas that the APPG and we elected representatives have identified is that there are areas of deprivation where levels of vascular ill health and amputations are higher. What can be done to...
I thank the Minister for his generosity in giving us a chance to ask questions. One of the areas that the APPG and we elected representatives have identified is that there are areas of deprivation where levels of vascular ill health and amputations are higher. What can be done to...
The hon. Member is absolutely right. We have to keep ICBs and their commissioning powers accountable to local jurisdictions. I will say a bit more on that in due course, but we are on the same page.
To facilitate faster assessments we also need to speed up and make earlier diagnoses,...
The hon. Member is absolutely right. We have to keep ICBs and their commissioning powers accountable to local jurisdictions. I will say a bit more on that in due course, but we are on the same page.
To facilitate faster assessments we also need to speed up and make earlier diagnoses,...
I will be quick, because I know the Minister wants to wind up and I am sure he has plenty of things to do. He is talking powerfully about the digital offering that the Labour Government are providing to patients today in England and, more importantly, our ambitions for the...
I will be quick, because I know the Minister wants to wind up and I am sure he has plenty of things to do. He is talking powerfully about the digital offering that the Labour Government are providing to patients today in England and, more importantly, our ambitions for the...
In the humblest of terms, I would be very happy to visit and speak to my Scottish counterparts to ensure that they take that opportunity, and that any development, whether on compatibility, operability, the learnings from the NHS app in how we then develop NHS Online—that sounds a bit too...
In the humblest of terms, I would be very happy to visit and speak to my Scottish counterparts to ensure that they take that opportunity, and that any development, whether on compatibility, operability, the learnings from the NHS app in how we then develop NHS Online—that sounds a bit too...
The hon. Member for Glasgow South West (Dr Ahmed) has nabbed my request—it is not about green cheese, by the way, Minister. My request is that the kindness the Minister has extended in respect of the hon. Gentleman and the Scottish health service is also extended to us in Northern...
The hon. Member for Glasgow South West (Dr Ahmed) has nabbed my request—it is not about green cheese, by the way, Minister. My request is that the kindness the Minister has extended in respect of the hon. Gentleman and the Scottish health service is also extended to us in Northern...
I will take any excuse I can to come to Northern Ireland, and I hope my private office has noted that.
In closing, our approach to improving the treatment of vascular diseases is closely aligned with the reforms in the APPG report and the APPG’s ambitions. I know that, of course,...
I will take any excuse I can to come to Northern Ireland, and I hope my private office has noted that.
In closing, our approach to improving the treatment of vascular diseases is closely aligned with the reforms in the APPG report and the APPG’s ambitions. I know that, of course,...
I thank everyone for their contributions, including the hon. Member for Broxtowe (Juliet Campbell). It is perhaps disquieting to understand that the hon. Lady has four times the number of people with vascular health issues in her constituency compared with elsewhere. That indicates a level of deprivation that is seen...
I thank everyone for their contributions, including the hon. Member for Broxtowe (Juliet Campbell). It is perhaps disquieting to understand that the hon. Lady has four times the number of people with vascular health issues in her constituency compared with elsewhere. That indicates a level of deprivation that is seen...
To ask the Secretary of State for Health and Social Care, with reference to her Department's press release entitled New heart disease and strokes plan to save thousands of lives, published on 7 July 2026, whether she plans to make continuous glucose monitoring available to participants in the NHS Diabetes...
To ask the Secretary of State for Health and Social Care, with reference to her Department's press release entitled New heart disease and strokes plan to save thousands of lives, published on 7 July 2026, whether she plans to make continuous glucose monitoring available to participants in the NHS Diabetes...
I refer the Hon Member to the answer provided to the Hon Member for West Dorset on 4 February 2026 in response to Question 106435.
To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential merits of extending eligibility for continuous glucose monitoring to people with pre-diabetes and those with early Type 2 diabetes.
To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential merits of extending eligibility for continuous glucose monitoring to people with pre-diabetes and those with early Type 2 diabetes.
I refer the Hon Member to the answer provided to the Hon Member for West Dorset on 4 February 2026 in response to Question 106435.
To ask the Secretary of State for Health and Social Care, what assessment her Department has made of the evidence on the effectiveness of continuous glucose monitoring in supporting behaviour change and reducing progression from pre-diabetes to Type 2 diabetes.
To ask the Secretary of State for Health and Social Care, what assessment her Department has made of the evidence on the effectiveness of continuous glucose monitoring in supporting behaviour change and reducing progression from pre-diabetes to Type 2 diabetes.
I refer the Hon Member to the answer provided to the Hon Member for West Dorset on 4 February 2026 in response to Question 106435.
To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential impact of wider access to continuous glucose monitoring on the level of health inequalities associated with Type 2 diabetes.
To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential impact of wider access to continuous glucose monitoring on the level of health inequalities associated with Type 2 diabetes.
I refer the Hon Member to the answer provided to the Hon Member for West Dorset on 4 February 2026 in response to Question 106435.
I thank my hon. Friend for that contribution. Having worked in neonatal care services and areas of specialised services in the NHS for 10 years, I understand that one of the benefits of NHS England was that it brought together highly specialised services, ensured consistent service specifications and uplifted the...
I thank my hon. Friend for that contribution. Having worked in neonatal care services and areas of specialised services in the NHS for 10 years, I understand that one of the benefits of NHS England was that it brought together highly specialised services, ensured consistent service specifications and uplifted the...
A Westminster Hall debate has been scheduled for 10 September 2026 on the potential merits of reform of the vascular sector.
A Westminster Hall debate has been scheduled for 10 September 2026 on the potential merits of reform of the vascular sector.
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to support research into the prevention, treatment and management of type 1 diabetes.
To ask the Secretary of State for Health and Social Care, what steps her Department is taking to support research into the prevention, treatment and management of type 1 diabetes.
To ask the Secretary of State for Health and Social Care, what assessment she has made of the contribution of UK research to improving outcomes for people with type 1 diabetes.
To ask the Secretary of State for Health and Social Care, what assessment she has made of the contribution of UK research to improving outcomes for people with type 1 diabetes.
To ask the Secretary of State for Health and Social Care, what assessment her Department has made of the potential benefits of funding immunotherapy research for people with early-stage type 1 diabetes.
To ask the Secretary of State for Health and Social Care, what assessment her Department has made of the potential benefits of funding immunotherapy research for people with early-stage type 1 diabetes.
To ask the Secretary of State for Health and Social Care, what steps her department is taking to increase localised preventive care and diagnostic capacity in parliamentary constituencies where UK Health Security Agency profile data indicates Type 2 diabetes prevalence exceeds 12 per cent, such as Leicester East.
To ask the Secretary of State for Health and Social Care, what steps her department is taking to increase localised preventive care and diagnostic capacity in parliamentary constituencies where UK Health Security Agency profile data indicates Type 2 diabetes prevalence exceeds 12 per cent, such as Leicester East.
To ask the Minister for the Cabinet Office, what estimate he has made of the annual productivity costs associated with diabetes including sickness absence, reduced economic participation and premature mortality.
To ask the Minister for the Cabinet Office, what estimate he has made of the annual productivity costs associated with diabetes including sickness absence, reduced economic participation and premature mortality.
To ask the Secretary of State for Health and Social Care, what steps he is taking to to ensure continuity of leadership for early-stage type 1 diabetes policy and service development during the transition of functions from NHS England to his Department.
To ask the Secretary of State for Health and Social Care, what steps he is taking to to ensure continuity of leadership for early-stage type 1 diabetes policy and service development during the transition of functions from NHS England to his Department.
The proposed abolition of NHS England and the associated transfer of its functions is subject to legislation and the will of Parliament. We are engaging with partners inside and outside the organisations as the process to design the future Department continues.
NHS England will continue to carry out its existing responsibilities and statutory functions during the transition period.
To ask the Secretary of State for Health and Social Care, what discussions he has had with NHS bodies regarding a future screening programme for early-stage type 1 diabetes.
To ask the Secretary of State for Health and Social Care, what discussions he has had with NHS bodies regarding a future screening programme for early-stage type 1 diabetes.
The Government is guided by the UK National Screening Committee (UK NSC), an independent scientific advisory committee which makes its recommendations based on internationally recognised criteria and a rigorous evidence review and consultation process. It is only where the UK NSC is confident that there is robust evidence that to screen would provide more good than harm that a screening programme is recommended, as all medical interventions carry an inherent risk.
The UK NSC received a submission via its 2024 open call process to consider screening for autoimmune type 1 diabetes through blood testing. Now that the National Institute for Health and Care Excellence has published its recommendation on the drug teplizumab, the UK NSC will look again at this open call submission and consider whether a fresh review of the evidence for type 1 diabetes screening should be undertaken.
The UK NSC is aware of the Early Surveillance for Autoimmune Diabetes study and looks forward to receiving the results of this study when the trial is complete.
To ask the Secretary of State for Health and Social Care, what steps he is taking to help ensure that the introduction of teplizumab contributes to reducing rates of diabetic ketoacidosis at diagnosis and inequalities in outcomes for people with type 1 diabetes.
To ask the Secretary of State for Health and Social Care, what steps he is taking to help ensure that the introduction of teplizumab contributes to reducing rates of diabetic ketoacidosis at diagnosis and inequalities in outcomes for people with type 1 diabetes.
Teplizumab is a new treatment for people aged eight years old and over with stage 2 type 1 diabetes, before the onset of symptoms. Its introduction represents a significant development in the treatment of type 1 diabetes and requires new clinical pathways and service arrangements to support safe and equitable access.
NHS England is working with integrated care boards, clinicians, patient groups, charities, and industry partners to support the development of these pathways. This work is already underway and is focused on helping local systems prepare for implementation and supporting consistent access across the country.
Evidence considered by the National Institute for Health and Care Excellence indicates that teplizumab can delay progression to stage 3 type 1 diabetes by almost three years on average. This gives people and their families additional time to understand the condition, prepare for future treatment and monitoring needs, and engage with clinical support before symptoms develop. Earlier identification and planned clinical management may help reduce the risk of diabetic ketoacidosis at diagnosis.
Integrated care boards will be required to make teplizumab available to all eligible individuals within the statutory 90 day implementation period. NHS England will continue to provide national leadership, including through a community of practice to share learning, support implementation, and ensure that health inequalities are identified and addressed appropriately.
To ask the Secretary of State for Science, Innovation and Technology, what assessment she has made of the UK's position globally in respect of research into beta cell preservation, regeneration and replacement therapies for type 1 diabetes.
To ask the Secretary of State for Science, Innovation and Technology, what assessment she has made of the UK's position globally in respect of research into beta cell preservation, regeneration and replacement therapies for type 1 diabetes.
Through UK Research and Innovation (UKRI), including UKRI’s Medical Research Council (MRC), the Government supports a broad portfolio of research relevant to Type 1 diabetes. This includes work on pancreatic biology, immunology, and cell replacement approaches, alongside wider research into the underlying mechanisms of the disease. Funding is awarded through open, competitive processes based on scientific excellence, ensuring the UK remains well placed to contribute to advances in areas such as beta cell therapies.
The Department of Health and Social Care also funds research through the National Institute for Health and Care Research, which supports high-quality research to improve the diagnosis, treatment and management of Type 1 diabetes.
To ask the Secretary of State for Health and Social Care, what data the Department holds on (a) the number and proportion of dopamine agonist-treated patients who report binge eating or marked weight gain, (b) weight and metabolic monitoring practices when dopamine agonists are started or doses increased, (c) the...
To ask the Secretary of State for Health and Social Care, what data the Department holds on (a) the number and proportion of dopamine agonist-treated patients who report binge eating or marked weight gain, (b) weight and metabolic monitoring practices when dopamine agonists are started or doses increased, (c) the...
The information requested on dopamine agonists is not held centrally nor held in the format requested and could only be obtained at disproportionate cost.
Dopamine agonists encompass a range of medicines authorised for the management of Parkinson’s disease, restless legs syndrome and endocrine disorders in the United Kingdom.
The product information approved by the Medicines and Healthcare products Regulatory Agency (MHRA) are designed to support safe use of the medicine by providing essential information and supporting discussions between patients and the healthcare professionals providing their care.
The MHRA continuously monitors the safety of medicines on the UK market to ensure that warnings and side-effects listed in the product information accurately reflect the available data. The MHRA is currently reviewing whether further action is needed to raise awareness of the existing warnings about impulse control disorders with dopamine agonists.
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help accelerate the translation of beta cell research into clinical trials and routine NHS care for people with type 1 diabetes.
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help accelerate the translation of beta cell research into clinical trials and routine NHS care for people with type 1 diabetes.
The Department delivers research into type 1 diabetes through the National Institute for Health and Care Research (NIHR).
As well as funding research itself, the Department invests significantly in centres of excellence which support and deliver health and care research. Collectively these form the NIHR infrastructure.
NIHR infrastructure supports research to help accelerate the development of treatments for type 1 diabetes. This includes, for example, research into earlier diagnosis and improved risk prediction to identify people who may benefit from disease-modifying or beta cell-preserving therapies. It also includes support for the development and testing of beta cell replacement, stem cell-derived islet, and immune-modulating therapies.
The NIHR infrastructure provides the end-to-end system needed to design, test, and deliver new therapies, playing a central role in delivery of clinical trials and ensuring that effective innovations are supported into practice at scale.
The NIHR is also supporting a new United Kingdom-wide Type 1 Diabetes Cell Therapy Clinical Trials Network. Funded by the Type 1 Diabetes Grand Challenge, this £5 million NIHR-backed programme aims to build a nationwide infrastructure across NIHR Biomedical Research Centres and Clinical Research Facilities for cell-therapy trials. This network is designed to address shared challenges in delivering cell therapy trials, ensuring all people with the condition gain access to the latest cutting-edge treatments as early as possible.
Motion that this House has considered the matter of reducing levels of premature deaths from heart disease and stroke. Agreed to on question.
Motion that this House has considered the matter of reducing levels of premature deaths from heart disease and stroke. Agreed to on question.
I beg to move,
That this House has considered the matter of reducing levels of premature deaths from heart disease and stroke.
It is an honour to serve under your chairmanship, Dame Siobhain. I thank hon. Members for attending the debate.
Cardiovascular disease remains one of the United Kingdom’s biggest killers and one...
I beg to move,
That this House has considered the matter of reducing levels of premature deaths from heart disease and stroke.
It is an honour to serve under your chairmanship, Dame Siobhain. I thank hon. Members for attending the debate.
Cardiovascular disease remains one of the United Kingdom’s biggest killers and one...
My hon. Friend is making an important and passionate speech, especially in the light of the personal circumstances that he mentioned. I agree with him about deprivation. Does he agree that access to fresh, affordable food is incredibly important, particularly in the most deprived areas? In Castlemilk in my constituency,...
My hon. Friend is making an important and passionate speech, especially in the light of the personal circumstances that he mentioned. I agree with him about deprivation. Does he agree that access to fresh, affordable food is incredibly important, particularly in the most deprived areas? In Castlemilk in my constituency,...
I absolutely agree. If we could get fresh food to more of our communities and young people, it would have a massive positive effect on dealing with CVD—that must be dealt with.
This debate could not be more timely. The Government have rightly identified CVD as one of the UK’s biggest...
I absolutely agree. If we could get fresh food to more of our communities and young people, it would have a massive positive effect on dealing with CVD—that must be dealt with.
This debate could not be more timely. The Government have rightly identified CVD as one of the UK’s biggest...